➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Baxter
Boehringer Ingelheim
McKesson

Last Updated: December 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AGN-2979

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AGN-2979?

AGN-2979 is an investigational drug.

There have been 49 clinical trials for AGN-2979. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Ocular Hypertension, Presbyopia, and Glaucoma, Open-Angle. The leading clinical trial sponsors are Allergan, Vitae Pharmaceuticals Inc., an Allergan affiliate, and Editas Medicine, Inc.

There are five US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for AGN-2979
TitleSponsorPhase
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular HypertensionAllerganPhase 1/Phase 2
Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With PresbyopiaAllerganPhase 1/Phase 2
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye DiseaseAllerganPhase 1/Phase 2

See all AGN-2979 clinical trials

Clinical Trial Summary for AGN-2979

Top disease conditions for AGN-2979
Top clinical trial sponsors for AGN-2979

See all AGN-2979 clinical trials

US Patents for AGN-2979

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AGN-2979   Start Trial Process for the preparation of 3-aryl-3-aminoalkyl-2,6-dioxohexahydropyridines G. D. Searle & Co. (Chicago, IL)   Start Trial
AGN-2979   Start Trial Memory-enhancing compositions containing dioxopiperidine derivatives National Research Development Corporation (London, GB2)   Start Trial
AGN-2979   Start Trial Process for the preparation of diethyl 2-]2-cyano-5-(dimethylamino)-2-(3-methoxyphenyl)-1,1-dimethylpentyl]prop andioate G. D. Searle & Co. (Chicago, IL)   Start Trial
AGN-2979   Start Trial Piperidin-2,6-dione bisulphate salts and their use for the treatment of stress related affective disorders Prestwick Pharmaceuticals, Inc. (Washington, DC)   Start Trial
AGN-2979   Start Trial Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders Prestwick Pharmaceuticals, Inc. (Washington, DC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AGN-2979

Drugname Country Document Number Estimated Expiration Related US Patent
AGN-2979 Canada CA2036968 2010-02-27   Start Trial
AGN-2979 European Patent Office EP0448972 2010-02-27   Start Trial
AGN-2979 Ireland IE910656 2010-02-27   Start Trial
AGN-2979 Japan JPH04211657 2010-02-27   Start Trial
AGN-2979 Japan JPH0694460 2010-02-27   Start Trial
AGN-2979 Portugal PT96883 2010-02-27   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Baxter
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.